Comparison Ofsecukinumab Vs Adalimumab in a Cost Per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthrisis at 48 Weeks from a Moroccan Perspective
Abstract
Authors
A Kooli P Gunda J Toumi E Nikoglou SM Jugl